sulfonylurea and glp 1 GLP-1 receptor agonists next-generation metabolic hormone therapies in chronic kidney disease How to transition a patient

We included patients who had been treated with an SGLT2i or GLP-1 RA for at least 6 months and analysed the efficacy, safety and cardio-renal outcomes 5 years after initiation of therapy

Testosterone therapy, particularly at supraphysiological doses, has been associated with increased haematocrit, polycythaemia, and potential cardiovascular events

A healthcare provider can also help someone determine if they can stay on the medication for type 2 diabetes or if its better to transition to a safer alternative medication for type 2 diabetes or prediabetes

Additional resources include Biocares Protein Meal Plans, GLP-1 grocery list, and protein calculator